NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership
Establishing whole genome sequencing centre in Singapore
Novogene, a commercial provider of genomic services and solutions with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte Ltd, a Singapore biotechnology company; and the Genome Institute of Singapore (GIS) announced today that NovogeneAIT genomics Singapore (NovogeneAIT) - a new joint venture between Novogene and AITbiotech - will establish a joint whole genome sequencing (WGS) centre at Biopolis, Singapore.
The new centre will provide Illumina HiSeq X based whole genome sequencing and bioinformatics analysis of human, plant and animal samples for biomedical and agricultural researchers. The centre will devote a major portion of its sequencing capability to support public research projects and empower super scale sequencing initiatives in Singapore and the region. In addition, NovogeneAIT will collaborate with GIS to develop new applications of next-generation sequencing, such as WGS solutions for cancer diagnosis and stratified cancer treatment.
"I am very excited and pleased to announce this significant new initiative with the Genome Institute of Singapore," stated Dr. Ruiqiang Li, CEO of Novogene. "The centre is the first major project for NovogeneAIT and is an important milestone for our company. We look forward to providing high-quality sequencing services in Singapore and to advancing important research initiatives that can benefit humanity."
"We are delighted to work with a local biotech company," said Prof. Ng Huck Hui, Executive Director of GIS. "Such public-private partnerships will prove to be highly beneficial as it leverages the strengths of both parties to advance genomic science and medicine in Singapore, as well as to create successful local biotech companies."
Most read news
Topics
Organizations
Other news from the department science
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Microscopy Today Innovation Award for ZEISS microscope
HeartBeat.bio raises € 4.5 million in Pre-Series A financing - New funds to drive development of organoid screening platform for cardiac drug discovery
New computer vision system designed to analyse cells in microscopy videos
Musical sensor shows bad medicine plays false note - Inspired by a musical instrument, the simple sensor can be constructed from common materials and used to detect adulterated or counterfeit drugs
PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12
How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body
LGC announces plans to expand forensic services with new facilities to be created in Runcorn, Cheshire
Synthetic Production of Potential Pharmaceuticals Dramatically Simplified by Scripps Research Team - Findings Could Expand Interest in Natural Products by Making Production More Cost-Effective
Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed
Brooks Instrument Joins Major Biotechnology Consortium Focused on Regenerative Drug Manufacturing - Brooks Instrument will contribute insights and precision fluid control technology to the Advanced Regenerative Manufacturing Institute’s BioFabUSA program
Promising discovery for a non-invasive early detection of Alzheimer's disease